$1.9 billion transaction is another boost for non-core IP deal-making in pharma
Sierra Oncology buyout is motivated by previously unwanted drug asset it bought for a $3 million upfront fee
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.